Slides: SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits?
Asian Cardio Diabetes Forum 2019Slides (presentation) - Apr. 7, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, MD Aachen, Germany - ACDF 2019
The slides are prepared and presented by the speaker during a PACE-CME educational program. The files are an educational service to registered PACE members only. PACE is not responsible for the content, opinions expressed in the slides
Prof. Nikolaus Marx is Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I, University Hospital Aachen. Prof. Nikolaus Marx became a board-certified internist, then cardiologist, before specialising in intensive care medicine in internal medicine at the University of Ulm. He was appointed Professor of Medicine / Cardiology and Head of the Department of Internal Medicine I at the University of Aachen in 2009. Professor Marx is a member of several organisations within the field of cardiology and diabetes, including the European Society of Cardiology, American Heart Association (AHA), German Diabetes Association and the European Association for the Study of Diabetes.
Prof Marx disclosures are, speaker: Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, Lilly, NovoNordisk. Research grant: Boehringer Ingelheim, MSD, Advisory board: Amgen, Bayer, Boehringer Ingelheim, Sanofi-Aventis, MSD, BMS, AstraZeneca, NovoNordisk. Prof marx declines all personal compensation from pharma or device companies